ABSTRACT
New COVID-19 epicenters have sprung up in Europe and US as the epidemic in China wanes. Many mechanistic models’ past predictions for China were widely off the mark (1, 2), and still vary widely for the new epicenters, due to uncertain disease characteristics. The epidemic ended in Wuhan, and later in South Korea, with less than 1% of their population infected, much less than that required to achieve “herd immunity”. Now as most countries pursue the goal of “suppressed equilibrium”, the traditional concept of “herd immunity” in epidemiology needs to be re-examined. Traditional model predictions of large potential impacts serve their purpose in prompting policy decisions on contact suppression and lockdown to combat the spread, and are useful for evaluating various scenarios. After imposition of these measures it is important to turn to statistical models that incorporate real-time information that reflects ongoing policy implementation and degrees of compliance to more realistically track and project the epidemic’s course. Here we apply such a tool, supported by theory and validated by past data as accurate, to US and Europe. Most countries started with a Reproduction Number of 4 and declined to around 1 at a rate highly dependent on contact-reduction measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding information.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this study are publicly available.
